An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

Mice treated p.o. with 5% dextran sodium sulfate develop a mild to moderate colitis characterized by focal areas of inflammation and crypt abscesses. Immunohistological analysis of colons from dextran sodium sulfate-treated mice revealed an increased expression of intercellular adhesion molecule 1 (ICAM-1) and infiltration of lymphocyte function antigen 1-positive cells. A murine-specific antisense oligonucleotide, ISIS 3082, was used to determine the role of ICAM-1 expression in the development of colitis. Prophylactic treatment of dextran sodium sulfate-treated mice with ISIS 3082 reduced the clinical signs of colitis in a dose-dependent manner, with maximal effects occurring at a dose of 1 mg/kg/day. Reductions in ICAM-1 immunostaining and infiltrating leukocytes were observed in colons of animals treated with 1 mg/kg ISIS 3082. Scrambled control oligonucleotides failed to modify the course of the disease. The ICAM-1 oligonucleotide also diminished the clinical severity of colitis in mice with established colitis. The toxicity of ISIS 3082 was assessed in normal CD-1 mice by administering the oligonucleotide intravenously every other day for 2 weeks. At pharmacologically relevant doses of ISIS 3082 (1 and 10 mg/kg), there were no signs of toxicity with respect to body and organ weights, clinical chemistry or hematology. At a dose of oligonucleotide 20- to 100-fold greater than maximal pharmacological doses, the oligonucleotide produced an increase in liver and spleen weights; a mild chronic inflammation in liver, lung and lymph nodes; monocytosis and an elevation of serum liver transaminases. These data suggest that an antisense oligonucleotide that reduces ICAM-1 expression could be effective in the therapy of inflammatory bowel disease in humans and that such an oligonucleotide would be safe at pharmacologically relevant doses.

• Publication year

  1997

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  1997-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/s0022-3565(24)36471-7PMID 9023316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

  1996cited by this paper
• Effect of different chemically modified oligodeoxynucleotides on immune stimulation.

  1996cited by this paper
• Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice.

  1996cited by this paper
• Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid

  1996cited by this paper
• Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.

  1994cited by this paper
• Adhesion molecules and inflammatory injury

  1994cited by this paper
• Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.

  1994cited by this paper
• Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides.

  1994cited by this paper
• Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

  1994cited by this paper
• Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7.

  1994cited by this paper
• Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.

  1994cited by this paper
• Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides.

  1994cited by this paper
• Synthesis of phosphorothioate-methylphosphonate oligonucleotide co-polymers.

  1994cited by this paper
• Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns.

  1994cited by this paper
• Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.

  1994influential reference
• EFFICIENT SYNTHESIS OF ANTISENSE OLIGODEOXYRIBONUCLEOTIDE PHOSPHOROTHIOATES

  1994cited by this paper
• CD54/intercellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation

  1994cited by this paper
• Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells.

  1994cited by this paper
• Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

  1993cited by this paper
• Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

  1993cited by this paper
• Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin

  1993cited by this paper
• Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear.

  1993cited by this paper
• Altered expression of cell adhesion molecules in uninvolved gut in inflammatory bowel disease

  1993cited by this paper
• Pathogenesis of ulcerative colitis.

  1993cited by this paper
• In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells.

  1993cited by this paper
• Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

  1993cited by this paper
• Medical therapies for inflammatory bowel disease

  1993cited by this paper
• A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients.

  1993cited by this paper
• Endothelial-leukocyte adhesion molecules.

  1993cited by this paper
• Therapeutic applications of oligonucleotides.

  1992cited by this paper
• Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis.

  1992cited by this paper
• Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

  1992cited by this paper
• Expression of vascular adhesion molecules in inflammatory bowel disease.

  1992cited by this paper
• Therapeutic Applications of Oligonucleotides

  1992cited by this paper
• Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes.

  1992cited by this paper
• Expression of intercellular adhesion molecule-1 in atherosclerotic plaques.

  1992cited by this paper
• Coronary Endothelial and Cardiac Protective Effects of a Monoclonal Antibody to Intercellular Adhesion Molecule‐1 in Myocardial Ischemia and Reperfusion

  1992cited by this paper
• Inflammatory bowel disease (Second of two parts)

  1991cited by this paper
• Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats.

  1991cited by this paper
• The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation.

  1991cited by this paper
• Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity.

  1991cited by this paper
• Inflammatory bowel disease (2)

  1991cited by this paper
• Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

  1991cited by this paper
• Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

  1991cited by this paper
• Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway obstruction in monkeys.

  1991cited by this paper
• A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

  1990cited by this paper
• A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice

  1990cited by this paper
• The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.

  1990cited by this paper
• Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma.

  1990cited by this paper
• ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18)

  1990cited by this paper
• In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts.

  1990cited by this paper
• Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment.

  1989cited by this paper
• Intercellular adhesion molecule 1 on liver allografts during rejection.

  1989cited by this paper
• Possible role of vascular endothelial cells in immune responses in colonic mucosa examined immunocytochemically in subjects with and without ulcerative colitis.

  1989cited by this paper
• Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor.

  1989cited by this paper
• T lymphocyte subpopulations and immunoglobulin-containing cells in the colonic mucosa of ulcerative colitis; a morphometric and immunohistochemical study.

  1988cited by this paper
• Lymphocyte activation in vivo in the intestinal mucosa of patients with Crohn's disease.

  1987cited by this paper
• Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).

  1987cited by this paper
• Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon.

  1987cited by this paper
• A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.

  1986cited by this paper
• Phenotypic analysis of lamina propria lymphocytes

  1986cited by this paper
• Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).

  1986cited by this paper
• A second site for Epstein‐Barr virus shedding: The uterine cervix

  1986cited by this paper
• Phenotypic analysis of lamina propria lymphocytes. Predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of suppressor-inducer phenotypes in Crohn's disease and control patients.

  1986cited by this paper
• Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2).

  1985influential reference
• Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease.

  1983cited by this paper
• Mapping of antigenic and functional epitopes on the alpha- and beta- subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1

  1983cited by this paper
• Antisense Oligonucleotides as Therapeutic Agents Is the Bullet Really Magical ?

  year unknowncited by this paper
• Pharmacokinetics , biodistribution , and stability of oligodeoxynucleotide phosphorothioates in mice ( antisense inhibition of gene expression / antiviral therapy / oligodeoxynucleotide uptake / human inimunodeficiency virus )

  year unknowncited by this paper

• Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis

  2024cites this paper
• Reduced Production of Pro-Inflammatory and Pro-Catabolic Factors by Human Serum Metabolites Derived from a Patented Saffron Extract Intake

  2024cites this paper
• Controlling in and out – the future of interfering with immune cell trafficking in inflammatory bowel disease

  2022cites this paper
• Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy

  2021cites this paper
• H19 Overexpression Improved Efficacy of Mesenchymal Stem Cells in Ulcerative Colitis by Modulating the miR-141/ICAM-1 and miR-139/CXCR4 Axes

  2021cites this paper
• Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases

  2020cites this paper
• BTT_A_257638 47..51

  2020cites this paper
• Potential Mechanisms of 3, 4-Oxo-Isopropylidene-Shikimic Acid in Ameliorating 2, 4, 6-Trinitrobenzenesulfonic Acid-Induced Colitis in Rats

  2019cites this paper
• Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease

  2019cites this paper
• DesigningTargeted F 4 / 80 Antibody Coated TNF-α siRNA Loaded Nanoparticles : A Novel Therapeutic Approach To Treat Inflammatory Bowel Disease

  2018cites this paper
• Recruitment of Inflammatory and Immune Cells in the Gut

  2018cites this paper
• Inflammatory bowel disease: new therapies from antisense oligonucleotides

  2018cites this paper
• Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.

  2018cites this paper
• Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.

  2018cites this paper
• Imaging the effects of the transient middle cerebral artery occlusion filament model on the recruitment of neutrophils with non‐invasive imaging techniques

  2017cites this paper
• 4 FORMULATION TECHNOLOGY CAN ENABLE ORAL DELIVERY OF NEW GENERATION MEDICINES FOR INFLAMMATORY BOWEL DISEASE

  2016cites this paper
• Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease

  2015cites this paper
• Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.

  2015cites this paper
• Protective effect of alcoholic extract of stem of Entada pursaetha in dextran sulphate sodium-induced colitis in mice.

  2015cites this paper
• The Gastrointestinal Circulation: Physiology and Pathophysiology.

  2015cites this paper
• Need for gender-specific pre-analytical testing: the dark side of the moon in laboratory testing.

  2015cites this paper
• Antibody Coated TNF-α siRNA Loaded Nanoparticles : A Novel Therapeutic Approach To Treat Inflammatory Bowel Disease

  2015cites this paper
• Targeting Integrins and Adhesion Molecules to Combat Inflammatory Bowel Disease

  2014influential citation
• Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

  2014cites this paper
• Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities.

  2014cites this paper
• Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes.

  2013cites this paper
• Adhesion Molecules as a Therapeutic Target in IBD

  2013cites this paper
• The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.

  2013cites this paper
• DesigningTargeted F4/80 Antibody Coated TNF-α siRNA Loaded Nanoparticles: A Novel Therapeutic Approach To Treat Inflammatory Bowel Disease

  2013cites this paper
• Chapter 68 – Inflammatory Bowel Disease

  2013cites this paper
• Recruitment of Inflammatory and Immune Cells in the Gut: Physiology and Pathophysiology

  2012cites this paper
• Targeting T‐cell migration in inflammatory bowel disease

  2012cites this paper
• Shining a Light on Intestinal Traffic

  2011cites this paper
• Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models.

  2011cites this paper
• Stasis predisposes ileal pouch inflammation in a rat model of ileal pouch-anal anastomosis.

  2010cites this paper
• Plant-Derived Polysaccharide Supplements Inhibit Dextran Sulfate Sodium-Induced Colitis in the Rat

  2009cites this paper
• Carbon nanotubes in drug delivery: focus on infectious diseases

  2009cites this paper
• Carbon nanotubes in drug delivery: focus on infectious diseases.

  2009cites this paper
• Leukocyte adhesion molecules in animal models of inflammatory bowel disease

  2008cites this paper
• Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD

  2008cites this paper
• Biological agents for ulcerative colitis: Hypes and hopes

  2008cites this paper
• Lymphocyte homing and its role in the pathogenesis of IBD.

  2008cites this paper
• Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice1

  2007cites this paper
• TITLE: Oral antisense oligonucleotides to mitigate GI crypt survival post-irradiation A. SPECIFIC AIMS Gastrointestinal (GI) injury is a major cause and contributor of death after whole-body irradiation

  2007cites this paper
• Melphalan Reduces the Severity of Experimental Colitis in Mice by Blocking Tumor Necrosis Factor‐α Signaling Pathway

  2007cites this paper
• T cell-associated CD18 but not CD62L, ICAM-1, or PSGL-1 is required for the induction of chronic colitis.

  2007cites this paper
• The adenosine A2A receptor agonist CGS 21680 fails to ameliorate the course of dextran sulphate-induced colitis in mice

  2007cites this paper
• Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis.

  2006cites this paper
• A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis

  2006cites this paper
• ICAM‐1‐dependent pathways regulate colonic eosinophilic inflammation

  2006cites this paper
• Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis

  2006cites this paper
• Assessment of the Effects of ISIS 2302, an Anti-Sense Inhibitor of Human ICAM-1, on Cellular and Humoral Immunity in Mice

  2006cites this paper
• Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis

  2006cites this paper
• Melphalan in ultralow doses decreases the severity of experimental colitis in mice

  2006cites this paper
• Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left‐sided ulcerative colitis: a randomized, double‐blind, active‐controlled trial

  2006cites this paper
• Antisense therapy of MAdCAM‐1 for trinitrobenzenesulfonic acid‐induced murine colitis

  2006cites this paper
• NF-κB Activation Precedes Increases in mRNA Encoding Neurokinin-1 Receptor, Proinflammatory Cytokines, and Adhesion Molecules in Dextran Sulfate Sodium–Induced Colitis in Rats

  2005cites this paper
• The ICAM‐1 antisense oligonucleotide ISIS‐3082 prevents the development of postoperative ileus in mice

  2005influential citation
• Intestinal Antiinflammatory Effects of Thiazolidenedione Peroxisome Proliferator‐Activated Receptor‐&ggr; Ligands on T Helper Type 1 Chemokine Regulation Include Nontranscriptional Control Mechanisms

  2005cites this paper
• Technology evaluation: alicaforsen (Isis).

  2005cites this paper
• NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats.

  2005cites this paper
• Cell biology and clinical implications of adhesion molecules in colorectal diseases: Colorectal cancers, infections and inflammatory bowel diseases

  2004cites this paper
• A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

  2004cites this paper
• escalating dose study of alicaforsen enema in active ulcerative colitis

  2004cites this paper
• Potential of Atelocollagen-Mediated Systemic Antisense Therapeutics for Inflammatory Disease

  2004cites this paper
• On the biological activity of anti-ICAM-1 oligonucleotides complexed to non-viral carriers.

  2004cites this paper
• Nuclear gastroenterology: novel techniques in clinical and experimental gastrointestinal mobility, IBD and hepatology

  2004cites this paper
• A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.

  2003cites this paper
• Administration of antisense oligonucleotides to Galpha(Q/11) reduces the severity of murine lupus.

  2003cites this paper
• Role of the microcirculation in chronic gut inflammation

  2003cites this paper
• An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice

  2003cites this paper
• Inosine reduces inflammation and improves survival in a murine model of colitis.

  2003cites this paper
• An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice.

  2003cites this paper
• Emerging biotherapies for inflammatory bowel disease

  2003cites this paper
• Correlation between Circulating Soluble ICAM-1 and Prednisolone-induced Amelioration of Ulcerative Colitis

  2003cites this paper
• The expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition

  2003cites this paper
• Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis.

  2003cites this paper
• Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-α in Two Murine Models of Colitis

  2003cites this paper
• Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice.

  2003cites this paper
• New therapeutic targets in Inflammatory Bowel Disease (IBD): Cell Adhesion Molecules

  2003cites this paper
• The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis.

  2003cites this paper
• Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes

  2003cites this paper
• Amelioration of Chronic and Spontaneous Intestinal Inflammation with an Antisense Oligonucleotide (ISIS 9125) to Intracellular Adhesion Molecule-1 in the HLA-B27/β2 Microglobulin Transgenic Rat Model

  2002cites this paper
• Antisense-Mediated Inhibition of ICAM-1 Expression: A Therapeutic Strategy Against Inflammation of Human Periodontal Tissue

  2002cites this paper
• Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

  2002cites this paper
• Interaktion von Leukozyten mit endothelialen Adhäsionsmolekülen und ihre Inhibition durch Expression von konkurrierenden Fusionsproteinen

  2002cites this paper
• Comparison of the New OPS Imaging Technique with Intravital Microscopy: Analysis of the Colon Microcirculation

  2002cites this paper
• Chronic inflammation alters protein metabolism in several organs of adult rats.

  2002cites this paper
• ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease

  2002cites this paper
• PParγ Ligands and Intestinal Inflammation

  2002cites this paper
• Comparison of the New OPS Imaging Technique with Intravital Microscopy: Analysis of the Colon Microcirculation

  2002cites this paper
• Pouchitis in a Rat Model of Ileal J Pouch–Anal Anastomosis

  2002cites this paper
• Leukocyte rolling is exclusively mediated by P‐selectinin colonic venules

  2002cites this paper
• bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver.

  2002cites this paper
• Inducing neutrophil recruitment in the liver of ICAM-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1

  2002cites this paper
• Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

  2002cites this paper
• Opioid Control of Inflammatory Pain Regulated by Intercellular Adhesion Molecule-1

  2002influential citation
• INFLAMMATORY BOWEL DISEASE Double blind , placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide , alicaforsen ( ISIS 2302 ) , in active steroid dependent Crohn ’ s disease

  2002cites this paper
• Spatial heterogeneity of TNF-alpha-induced T cell migration to colonic mucosa is mediated by MAdCAM-1 and VCAM-1.

  2002cites this paper
• Endothelial cells at inflammatory sites as target for therapeutic intervention.

  2002cites this paper